Your browser version may not work well with NCBI's Web applications. More information here...
1: Clin Chem. 1996 Jan;42(1):39-44.Click here to read Links

Evaluation of clinical assays for measuring high-dose methotrexate in plasma.

Albertioni F, Rask C, Eksborg S, Poulsen JH, Pettersson B, Beck O, Schroeder H, Peterson C.

Department of Clinical Pharmacology, Karolinska Hospital, Stockholm, Sweden. Freidoun_Albertioni@micforum.ki.se

Four routine assays commonly used for monitoring plasma methotrexate (MTX) during high-dose therapy were validated by HPLC as the comparison method. MTX and its main metabolite, 7-hydroxymethotrexate (7-OHMTX), were analyzed by HPLC with postcolumn derivatization and fluorometric detection. About 200 clinical plasma samples from 13 children with acute lymphoblastic leukemia who received 5-8 g/m2 MTX as 24-h infusions were analyzed. The fraction of measured concentrations of MTX that were within 75-125% of the values obtained by HPLC were 64.5% for enzyme inhibition assay, 56.4% for fluorescence polarization immunoassay with polyclonal antibodies (FPIA1; Abbott), 58.9% for FPIA2 (with monoclonal antibodies; Abbott), and 46.4% for enzyme-multiplied immunoassay (Emit; Syva). All nonchromatographic procedures were subject to interferences from MTX plasma metabolites or endogenous substances. The interference from 7-OHMTX was, however, somewhat less pronounced for FPIA2 (monoclonal) than for FPIA1 (polyclonal).

PMID: 8565230 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Methotrexate (Rheumatrex® , Trexall® )

    Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments. Methotrexate is also used along with rest, physica...

  • Source: AHFS Consumer Medication Information